Key Speakers
• Sophie Crousse, Director - Government Affairs, Europe, GlaxoSmithKline Consumer Healthcare
• Prof Onno Van Schayck, Scientific Director - CAPHRI (Care and Public Health Research Institute), University Maastricht – Netherlands
• Dr Raafat Fahim, President and CEO, Nabi Biopharmaceuticals
• Alison Cox, Project Director, Framework Convention Alliance (Action on Smoking & Health)
• Florence Berteletti Kemp, Director, Smoke Free Partnership
• Dan Tickle, Chief Executive, No Smoking Day
• Ashok Narasimhan, President, Zenara Pharma
• Jean King, Director of Tobacco Control, Cancer Research UK
• Tim Roberts, Stop-Smoking Manager, NHS
• Dr Mira V Doig, Laboratory & QA Manager, ABS Laboratories
Smoking cessation is among the most dynamic markets within the pharma, biotech and healthcare sector, and expected to grow despite the current economic times. According to visiongain’s ‘Smoking Cessation 2009-2024 report’, the evolution of NRTs - including neuroreceptor modulators, enzyme inhibitors and therapeutic vaccines - will push worldwide sales of smoking cessation drugs to $1.5 billion by 2010, with majority of revenues coming from the NRTs.
Recently, the current marketed drugs have come under strict FDA regulations highlighting low safety and efficacy of existing smoking cessation products. These restraints will further strengthen the scope for robust drug pipeline and newer opportunities that will revolutionise the global smoking cessation landscape.
Following the success of our series of conferences in the UK and US, the 4th Annual Smoking Cessation conference, will discuss current challenges, unmet medical needs, scope and future treatments in the smoking cessation market. With an impressive line-up of speakers and topical themes, you will gain an international perspective on the future tobacco control activities and treatments to reduce the impact of smoking globally.
Why Attend?
By attending this conference you will gain knowledge on:
• Awareness of NRT and government/NGO efforts to tackle the tobacco use in BRIC countries
• EU perspective on price and tax measures: New proposal for the Tobacco Tax Directive
• Accurate measurements to support the assessment of nicotine addiction
• Therapeutic vaccines – revolutionising the face of anti-smoking market
• Combination therapies of smoking cessation
• Effective use of mobile technology towards a ‘Smokefree’ UK
• Monitoring smoking cessation programmes
Who should attend?
VPs, Directors, Heads and Managers of:
• Smoking Cessation
• Anti-smoking Products
• NRTs
• Tobacco Risk/Control
• Tobacco Research
• Clinical Trials
• Clinical Pharmacology
• Pharmacotherapy
• Drug Delivery
• Research & Development
• Scientific Affairs
• Primary Care
• Respiratory
• COPD
• Therapeutics
• Drug Addiction
• Health Improvement
• Epidemiology
• Consumer Insights
• Outcomes Research
• Product Development
• Pricing
• Marketing/Sales
• Public Affairs/Branding/Advertising
• Regulatory Affairs
Members of:
• Pharma, Biotech & Healthcare Organisations
• Government - Department of Health, NHS PCTs
• Non-profit Organisations/Associations
• Advertising/Public Relations Bodies
• Hospitals
